


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
F-STAR ENTERED INTO LICENCE AGREEMENT WITH TAKEDA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that F-star Therapeutics, Inc. (“**F-star**”), a group company of Sino Biopharm, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.

Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an immuno-oncology target using F-star’s proprietary Fcab[™] and mAb²[™] platforms. Takeda will be responsible for all research, development and commercialisation activities under the agreement. F-star will receive an upfront licence fee and is eligible to receive potential future development and commercialization milestone payments, plus royalties on annual net sales.

This licence agreement represents the second option that Takeda has exercised under an evaluation and licence agreement with F-star that was entered into in July 2021. F-star and Takeda entered into a licence agreement for a different bispecific antibody in July 2022.

This second licence agreement with Takeda provides further validation of the enormous potential of F-star's mAb²™ platform to produce multiple next-generation bispecific antibody therapeutics, and demonstrates the dedication of F-star and Takeda to a shared vision of developing pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 22 March 2023

As at the date of this announcement, the Board of the Company comprises seven executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.